PARP-inhibitors in a non?oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open - 27/10/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Graphical abstract |
Highlights |
• | PARPi can work as powerful anti-inflammatory molecules. |
• | SARS-CoV-2 triggers pro-inflammatory and prothrombotic cascades. |
• | PARPi could be successfully used as antithrombotic drugs in severe or moderate forms of COVID-19. |
• | PARPi have shown potential anti-viral replication activities |
Abstract |
In the last three months, the whole scientific community has shifted its focus to the fight against the COVI-2 infection (COVID-19) trying to use different medications to save the patients' life. In some studies, the results were completely inconclusive, as in the case of chloroquine. However, the recent discovery on benefits deriving from use of such anticoagulants for Covid-19 patients, has increased the success of patients’ treatment. Among lots of old and new drugs, PARP-inhibitors were not considered as possible option in the treatment of Covi-2 infection, being the latter able to induce the inflammatory and thrombotic cascades. Since PARP-inhibitors are able to reduce and block mechanisms leading to thrombosis and inflammation, they could be used as antithrombotic medications. Therefore, the present brief report is aimed to open the discussion on the potentials of PARP-inhibitors in non-oncological settings, like Covid-19.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, PARP-inhibitors, PARP, COVi-2
Vol 130
Article 110536- octobre 2020 Retour au numéro
Article précédent
- Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
- Yahao Zhang, Yanghui Zhang, Zhiyu Liu, Bin Zhang, Guizhi Liu, Kui Chen
- Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19
- Ulf Norinder, Astrud Tuck, Kalle Norgren, Vesna Munic Kos
Bienvenue sur EM-consulte, la référence des professionnels de santé.